Literature DB >> 30547416

Mitochondrial Impairment in Oligodendroglial Cells Induces Cytokine Expression and Signaling.

Miriam Scheld1, Athanassios Fragoulis2, Stella Nyamoya3,4, Adib Zendedel3, Bernd Denecke5, Barbara Krauspe6, Nico Teske4, Markus Kipp7, Cordian Beyer3, Tim Clarner3.   

Abstract

Widespread inflammatory lesions within the central nervous system grey and white matter are major hallmarks of multiple sclerosis. The development of full-blown demyelinating multiple sclerosis lesions might be preceded by preactive lesions which are characterized by focal microglia activation in close spatial relation to apoptotic oligodendrocytes. In this study, we investigated the expression of signaling molecules of oligodendrocytes that might be involved in initial microglia activation during preactive lesion formation. Sodium azide was used to trigger mitochondrial impairment and cellular stress in oligodendroglial cells in vitro. Among various chemokines and cytokines, IL6 was identified as a possible oligodendroglial cell-derived signaling molecule in response to cellular stress. Relevance of this finding for lesion development was further explored in the cuprizone model by applying short-term cuprizone feeding (2-4 days) on male C57BL/6 mice and subsequent analysis of gene expression, in situ hybridization and histology. Additionally, we analyzed the possible signaling of stressed oligodendroglial cells in vitro as well as in the cuprizone mouse model. In vitro, conditioned medium of stressed oligodendroglial cells triggered the activation of microglia cells. In cuprizone-fed animals, IL6 expression in oligodendrocytes was found in close vicinity of activated microglia cells. Taken together, our data support the view that stressed oligodendrocytes have the potential to activate microglia cells through a specific cocktail of chemokines and cytokines among IL6. Further studies will have to identify the temporal activation pattern of these signaling molecules, their cellular sources, and impact on neuroinflammation.

Entities:  

Keywords:  Cytokines; IL6; Microglia; Multiple sclerosis; Oligodendrocytes; Preactive lesions

Mesh:

Substances:

Year:  2018        PMID: 30547416     DOI: 10.1007/s12031-018-1236-6

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  6 in total

1.  Oligodendrocytes modulate the immune-inflammatory response in EAE via TNFR2 signaling.

Authors:  Pernille M Madsen; Haritha L Desu; Juan Pablo de Rivero Vaccari; Yoleinny Florimon; Ditte G Ellman; Robert W Keane; Bettina H Clausen; Kate L Lambertsen; Roberta Brambilla
Journal:  Brain Behav Immun       Date:  2019-11-27       Impact factor: 7.217

2.  Nrf2 deficiency increases oligodendrocyte loss, demyelination, neuroinflammation and axonal damage in an MS animal model.

Authors:  Anna Nellessen; Stella Nyamoya; Adib Zendedel; Alexander Slowik; Christoph Wruck; Cordian Beyer; Athanassios Fragoulis; Tim Clarner
Journal:  Metab Brain Dis       Date:  2019-09-16       Impact factor: 3.584

3.  Relationship of Iron Metabolism and Short-Term Cuprizone Treatment of C57BL/6 Mice.

Authors:  Edina Pandur; Ramóna Pap; Edit Varga; Gergely Jánosa; Sámuel Komoly; Judit Fórizs; Katalin Sipos
Journal:  Int J Mol Sci       Date:  2019-05-07       Impact factor: 5.923

Review 4.  Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination.

Authors:  Martin Zirngibl; Peggy Assinck; Anastasia Sizov; Andrew V Caprariello; Jason R Plemel
Journal:  Mol Neurodegener       Date:  2022-05-07       Impact factor: 18.879

5.  Autoimmune neuroinflammation triggers mitochondrial oxidation in oligodendrocytes.

Authors:  Jasmin Steudler; Timothy Ecott; Daniela C Ivan; Elisa Bouillet; Sabrina Walthert; Kristina Berve; Tobias P Dick; Britta Engelhardt; Giuseppe Locatelli
Journal:  Glia       Date:  2022-06-28       Impact factor: 8.073

6.  Oligodendrocyte Lineage Marker Expression in eGFP-GFAP Transgenic Mice.

Authors:  Newshan Behrangi; Peter Lorenz; Markus Kipp
Journal:  J Mol Neurosci       Date:  2020-12-21       Impact factor: 3.444

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.